Bromide

Bromide

SCHEMBL299633

C=CC[n+]1ccc2ccccc2c1.[Br-]

nearest known ligand 0.72

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1

The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
ACHE known ✓ P22303 15/20 0.72
BCHE P06276 17/20 0.72

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL131315 0.98 ACHE (0.69) BCHEACHE
Hydrochloric Acid SCHEMBL1099708 0.96 ACHE (0.72) BCHEACHE
Iodide SCHEMBL3434198 0.96 ACHE (0.67) BCHEACHE
SCHEMBL4389303 0.91 ACHE (0.61) BCHEACHE
SCHEMBL29657227 0.91 ACHE (0.61) BCHEACHE
Bromide SCHEMBL10988989 0.76 BCHE (0.44) BCHEACHE
SCHEMBL10615714 0.76 ACHE (0.76) BCHEACHE
SCHEMBL25613361 0.74 BCHE (0.83) BCHEACHE
Bromide SCHEMBL14937532 0.72 BCHE (1.00) BCHEACHE
Bromide SCHEMBL4890409 0.72 BCHE (1.00) BCHEACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 492 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210093724-A1 TOPICAL ANTI-ACNE COMPOSITION CONCEPT MATRIX SOLUTIONS 2021-04-01 US claimed
WO-2016010984-A2 COMPOSITIONS AND METHODS FOR TREATING ROSACEA TISSUE TECH, INC. (US) 2016-01-21 WO claimed
US-20160008295-A1 COMPOSITIONS AND METHODS FOR TREATING ROSACEA TISSUE TECH, INC. 2016-01-14 US claimed
US-20140154342-A1 SANDALWOOD OIL AND ITS USES RELATED TO SKIN DISORDERS SANTALIS PHARMACEUTICALS INC. (US) 2014-06-05 US claimed
EP-2736504-A1 SANDALWOOD OIL AND ITS USES RELATED TO SKIN DISORDERS Santalis Pharmaceuticals Inc. (US) 2014-06-04 EP claimed
US-20130203969-A1 USE OF SMALL MOLECULES IN METHODS FOR PURIFICATION OF BIOMOLECULES EMD MILLIPORE CORPORATION (US) 2013-08-08 US claimed
WO-2013016656-A1 SANDALWOOD OIL AND ITS USES RELATED TO SKIN DISORDERS SANTALIS PHARMACEUTICALS INC. (US) 2013-01-31 WO claimed
US-5830488-A QUICK-DRYING; ALCOHOL, CATIONIC DISINFECTANT AND SILICONE SHISEIDO CO., LTD. (JP) 1998-11-03 US claimed
WO-1997000609-A1 METHOD FOR INCREASING THE EFFICACY OF AN ODOR MASKING AGENT HENKEL CORPORATION (US) 1997-01-09 WO claimed
US-5089252-A Amphoteric polymer of betainised dialkylaminoalkyl acrylate or dialkylaminoalkyl acrylamide and cationic deriative L'OREAL (FR) 1992-02-18 US claimed
JP-56030902-A None JP disclosed
CN-118159133-A Permanent disinfection composition and method for permanent disinfection 法国特种经营公司 2024-06-07 CN disclosed
WO-2024092394-A1 ANTIMICROBIAL FOAM HAND SOAP COMPOSITIONS WITH COLOR INDICATOR SYSTEMS ECOLAB USA INC. (US) 2024-05-10 WO disclosed
WO-2024085105-A1 ANTI-INFLAMMATORY AGENT, TNF-α PRODUCTION INHIBITOR, INTERLEUKIN-10 PRODUCTION PROMOTOR, SKIN EXTERNAL APPLICATION COMPOSITION, FOOD OR BEVERAGE COMPOSITION, METHOD FOR PREVENTING, AMELIORATING, OR TREATING INFLAMMATORY DISEASES, AND USE OF PLANT-DERIVED POLYAMINE-CONTAINING EXTRACT FOR MANUFACTURING ANTI-INFLAMMATORY AGENT 東洋紡株式会社 2024-04-25 WO disclosed
US-11964042-B2 Additive for medicinal agents NIPPON SHOKUBAI CO., LTD. (JP) 2024-04-23 US disclosed
US-4163038-A ACTIVE INGREDIENT AND BLOWING AGENT EARTH CHEMICAL COMPANY, LIMITED (JP) 1979-07-31 US disclosed
US-4051234-A BIS-GUANIDINE COMPOUND, ETHYLENEDIAMINEDIACETIC ACID OR SALT AS CHELATOR THE PROCTER & GAMBLE COMPANY (US) 1977-09-27 US disclosed
US-4025616-A Oral compositions for plaque, caries and calculus retardation with reduced staining tendencies THE PROCTER & GAMBLE COMPANY (US) 1977-05-24 US disclosed
US-3937807-A BISBIGUANIDE COMPOUND THE PROCTER & GAMBLE COMPANY (US) 1976-02-10 US disclosed
US-3934002-A BIS-GUANIDE THE PROCTER & GAMBLE COMPANY (US) 1976-01-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210093724-A1 TOPICAL ANTI-ACNE COMPOSITION CUTA, EBP, CNR2 ACHE 3814/4885BCHE 3481/4885
US-11964042-B2 Additive for medicinal agents ADM2, NQO1, MRPL21 ACHE 508/4885BCHE 1848/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.